# Amtagvi

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/amtagvi
Canonical HTML page: https://gethealthbrief.com/entity/amtagvi

## Timeline

- **2026-02-23**: Q4 Earnings Preview — Analysts project significant revenue growth from Amtagvi sales.
- **2025-01-01**: Commercial Expansion — Iovance scales ATC network to over 50 centers nationwide.
- **2024-02-16**: FDA Approval — Amtagvi receives accelerated approval for metastatic melanoma.

## Recent coverage (1 stories)

### Iovance Biotherapeutics Q4 Earnings: Amtagvi Commercial Scaling in Focus
2026-02-23 16:59:47 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Iovance Biotherapeutics is set to report Q4 2025 results, with investors laser-focused on the commercial trajectory of Amtagvi, the first FDA-approved TIL therapy. The report will provide critical data on treatment center onboarding, patient enrollment, and the company's path toward profitability in the cell therapy space.
Full story: https://gethealthbrief.com/story/iovance-biotherapeutics-q4-2025-earnings-preview-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.